{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:20:30Z","timestamp":1789597230264,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,11]],"date-time":"2013-08-11T00:00:00Z","timestamp":1376179200000},"content-version":"vor","delay-in-days":344,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.euroneuro.2012.01.006","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T00:35:27Z","timestamp":1330994127000},"page":"625-631","source":"Crossref","is-referenced-by-count":49,"title":["Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes"],"prefix":"10.1016","volume":"22","author":[{"given":"Jelle","family":"Vehof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibert","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmar","family":"Al Hadithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz Z.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Snieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.euroneuro.2012.01.006_bb0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ng.171","article-title":"Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database","volume":"40","author":"Allen","year":"2008","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.01.006_bb0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archpsyc.1992.01820080023004","article-title":"The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology","volume":"49","author":"Andreasen","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2012.01.006_bb0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008571-200405000-00005","article-title":"Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics","volume":"14","author":"Anttila","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"8970","key":"10.1016\/j.euroneuro.2012.01.006_bb0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(95)92168-0","article-title":"Association between clozapine response and allelic variation in 5-HT2A receptor gene","volume":"346","author":"Arranz","year":"1995","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2012.01.006_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(96)13094-9","article-title":"Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine","volume":"217","author":"Arranz","year":"1996","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.mp.4000348","article-title":"Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine","volume":"3","author":"Arranz","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.01.006_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","article-title":"Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response","volume":"32","author":"Arranz","year":"1998","journal-title":"Schizophr. Res."},{"issue":"9215","key":"10.1016\/j.euroneuro.2012.01.006_bb0045","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","article-title":"Pharmacogenetic prediction of clozapine response","volume":"355","author":"Arranz","year":"2000","journal-title":"Lancet"},{"issue":"9238","key":"10.1016\/j.euroneuro.2012.01.006_bb0050","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(05)74275-6","article-title":"Difficulties in replication of results","volume":"356","author":"Arranz","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1023\/A:1008634632501","article-title":"Hyperhomocysteinaemia and associated disease","volume":"19","author":"Bakker","year":"1997","journal-title":"Pharm. World Sci."},{"issue":"10","key":"10.1016\/j.euroneuro.2012.01.006_bb0060","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1176\/appi.ajp.161.10.1798","article-title":"Interaction of COMT (Val(108\/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia","volume":"161","author":"Bertolino","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"no. 2","key":"10.1016\/j.euroneuro.2012.01.006_bb0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","article-title":"Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?","volume":"vol. 30","author":"Derks","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2012.01.006_bb0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197503062921001","article-title":"Folate-responsive homocystinuria and \u201cschizophrenia\u201d. A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity","volume":"292","author":"Freeman","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.01.006_bb0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1124\/mol.66.5.1293","article-title":"His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation","volume":"66","author":"Hazelwood","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-005-2223-5","article-title":"Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory\/intolerant populations","volume":"181","author":"Hwang","year":"2005","journal-title":"Psychopharmacology"},{"issue":"9018","key":"10.1016\/j.euroneuro.2012.01.006_bb0090","first-page":"1831","article-title":"5HT 2a receptor T102C polymorphism and schizophrenia","volume":"347","author":"Jonsson","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0095","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.01.006_bb0100","first-page":"141","article-title":"T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability","volume":"24","author":"Joober","year":"1999","journal-title":"J. Psychiatry Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.mp.4000724","article-title":"Association between the methylenetetrahydrofolate reductase 677C\u2013>T missense mutation and schizophrenia","volume":"5","author":"Joober","year":"2000","journal-title":"Mol. Psychiatry"},{"issue":"4\u20135","key":"10.1016\/j.euroneuro.2012.01.006_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3956(00)00018-2","article-title":"DRD3 and DAT1 genes in schizophrenia: an association study","volume":"34","author":"Joober","year":"2000","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2012.01.006_bb0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01213011-200506000-00003","article-title":"The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects","volume":"15","author":"Laakso","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"issue":"10","key":"10.1016\/j.euroneuro.2012.01.006_bb0120","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.jcp.0000150226.84371.76","article-title":"Dopamine D3 receptor Ser9Gly polymorphism and risperidone response","volume":"25","author":"Lane","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","article-title":"DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients","volume":"163","author":"Lencz","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2012.01.006_bb0135","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(98)00187-5","article-title":"Serotonergic basis of antipsychotic drug effects in schizophrenia","volume":"44","author":"Lieberman","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0140","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","article-title":"Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system","volume":"225","author":"Lundstrom","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1176\/ajp.153.8.1092","article-title":"Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine","volume":"153","author":"Malhotra","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.mp.4000288","article-title":"The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response","volume":"3","author":"Malhotra","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"8982","key":"10.1016\/j.euroneuro.2012.01.006_bb0155","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(95)91785-3","article-title":"Genetic variation of 5-HT2A receptor and response to clozapine","volume":"346","author":"Masellis","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.01.006_bb0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1526-4610.2009.01484.x","article-title":"The relationship between homocysteine and genes of folate-related enzymes in migraine patients","volume":"50","author":"Oterino","year":"2010","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.euroneuro.2012.01.006_bb0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.06.020","article-title":"The -1438A\/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity","volume":"56","author":"Parsons","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.01.006_bb0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.01.006_bb0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01271539","article-title":"Homocysteinemia is a common feature of schizophrenia","volume":"100","author":"Regland","year":"1995","journal-title":"J. Neural Transm. Gen. Sect."},{"issue":"2","key":"10.1016\/j.euroneuro.2012.01.006_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.euroneuro.2004.07.001","article-title":"Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response","volume":"15","author":"Reynolds","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.01.006_bb0190","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","article-title":"Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene","volume":"158","author":"Schafer","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0924-977X(99)00044-9","article-title":"Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients","volume":"10","author":"Scharfetter","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2012.01.006_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","article-title":"Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions","volume":"31","author":"Schwartz","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0895-4356(96)00312-5","article-title":"Statistical assessment of ordinal outcomes in comparative studies","volume":"50","author":"Scott","year":"1997","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.euroneuro.2012.01.006_bb0210","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF02346178","article-title":"Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia","volume":"97","author":"Shaikh","year":"1996","journal-title":"Hum. Genet."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2012.01.006_bb0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2008.06.016","article-title":"Genetic associations with schizophrenia: meta-analyses of 12 candidate genes","volume":"104","author":"Shi","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001756-199512000-00041","article-title":"Association between clozapine response and allelic variation in the 5-HT2C receptor gene","volume":"7","author":"Sodhi","year":"1995","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00213-002-1084-4","article-title":"Clinical applications of pharmacogenetics in psychiatry","volume":"162","author":"Staddon","year":"2002","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.01.006_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.20045","article-title":"Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia","volume":"124B","author":"Szekeres","year":"2004","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2012.01.006_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1192\/bjp.156.1.17","article-title":"Heterogeneity of schizophrenia conceptual models and analytic strategies","volume":"156","author":"Tsuang","year":"1990","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2012.01.006_bb0240","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","article-title":"SCAN. Schedules for clinical assessment in neuropsychiatry","volume":"47","author":"Wing","year":"1990","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T18:46:02Z","timestamp":1593801962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0924977X12000247"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.01.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}